Adipotide
Pro-apoptotic targeting peptide (prohibitin-homing motif fused to a KLAKLAK apoptotic domain)
Adipotide (FTPP) is an experimental targeting peptidomimetic aimed at the vasculature supporting white adipose tissue. In preclinical studies it induced fat loss by triggering apoptosis of the blood vessels feeding fat. It is preclinical/research-only, with notable renal toxicity signals in animal work.
Mechanism under study
A homing motif (CKGGRAKDC) binds prohibitin/annexin-A2 displayed on the endothelium of white-fat blood vessels, delivering a fused D(KLAKLAK)2 pro-apoptotic peptide that disrupts mitochondrial membranes, pruning the fat's blood supply and causing adipocyte loss.
Research-reported dosing
No established human dosing. Rhesus primate studies used subcutaneous doses reported around 0.43 mg/kg/day for about 4 weeks, with reversible kidney effects observed. Preclinical/research-only; not approved and not validated for human use.
10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit is approximately 0.05 mg (50 mcg). Reported animal renal toxicity underscores that this is a research compound only.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Adipotide FAQ
What is Adipotide?
Adipotide (FTPP) is an experimental targeting peptidomimetic aimed at the vasculature supporting white adipose tissue. In preclinical studies it induced fat loss by triggering apoptosis of the blood vessels feeding fat. It is preclinical/research-only, with notable renal toxicity signals in animal work.
What is the half-life of Adipotide?
Short in circulation (reported on the order of hours in animal work); human pharmacokinetics are not established.
What is the research-reported dosing for Adipotide?
No established human dosing. Rhesus primate studies used subcutaneous doses reported around 0.43 mg/kg/day for about 4 weeks, with reversible kidney effects observed. Preclinical/research-only; not approved and not validated for human use.
How is Adipotide reconstituted?
10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL (5 mg/mL); 1 unit is approximately 0.05 mg (50 mcg). Reported animal renal toxicity underscores that this is a research compound only.
Is Adipotide FDA-approved?
No — Adipotide is not FDA-approved and is sold for laboratory research use only.
References
Related peptides
AOD-9604
Modified growth-hormone fragment
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat metabolism without the full growth-promoting effects of intact GH.
Tesamorelin
Stabilized GHRH analog
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.
5-Amino-1MQ
Small-molecule NNMT inhibitor (not a peptide)
A small-molecule inhibitor of the enzyme NNMT — not a peptide — studied mainly in cell and animal models for its effects on fat-cell metabolism and its potential to preserve NAD+.
Semaglutide
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.